New combo therapy aims to tackle Hard-to-Treat myeloma
NCT ID NCT06121843
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 35 times
Summary
This early-stage study is testing a new cell therapy (arlocabtagene autoleucel) combined with other drugs in people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find safe doses and check for side effects. About 147 adults will take part to see if these combinations can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
Contact Phone: •••-•••-••••
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-••••
-
Laura and Isaac Perlmutter Cancer Center
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-••••
-
Local Institution - 0009
COMPLETEDNew York, New York, 10032, United States
-
Local Institution - 0023
WITHDRAWNPittsburgh, Pennsylvania, 15232, United States
-
Mayo Clinic in Arizona - Phoenix
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-••••
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-••••
-
Mayo Clinic in Rochester, Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact Phone: •••-•••-••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-••••
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
University Of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact Phone: •••-•••-••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294-3300, United States
Contact Phone: •••-•••-••••
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.